Ушбу иш иқтибос қилган ишлар

199 та иш

Иш: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram, James Lee, Erik Hayman +4
Мақола20122 иқтибос
ABI
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru, Terence J. Purdon, David R. Spriggs +2
Мақола20152 иқтибос
ABI
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang +17
Мақола20092 иқтибос
ABI
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Stefani Spranger, Robbert M. Spaapen, Yuanyuan Zha +4
Мақола20132 иқтибос
ABI
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33
Мақола20162 иқтибос
ABI
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu, Mien‐Chie Hung
Шарҳ мақола20162 иқтибос
ABI
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan +80
Мақола20172 иқтибос
ABI
Tumor Heterogeneity in Breast Cancer
Gulisa Turashvili, Edi Brogi
Шарҳ мақола20172 иқтибос
ABI
Biomarker concordance between primary colorectal cancer and its metastases
Dilraj Bhullar, Jorge Barriuso, S. Mullamitha +3
Шарҳ мақола20192 иқтибос
ABI
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie +1
Шарҳ мақола20192 иқтибос
ABI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38
Мақола20202 иқтибос
ABI
Memory T cells: strategies for optimizing tumor immunotherapy
Qingjun Liu, Zhongjie Sun, Ligong Chen
Шарҳ мақола20202 иқтибос
ABI
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner
Шарҳ мақола20212 иқтибос
ABI
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27
Мақола20212 иқтибос
ABI
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Brooke Prinzing, Caitlin C. Zebley, Christopher T. Petersen +24
Мақола20212 иқтибос
ABI
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
Lupeng Ye, Jonathan J. Park, Lei Peng +17
Мақола20222 иқтибос
ABI
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Jinge Zhou, Lei Sun, Yujie Jia +8
Мақола20222 иқтибос
ABI
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Zaoqu Liu, Zhaokai Zhou, Qin Dang +4
Шарҳ мақола20222 иқтибос
ABI
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute +4
Шарҳ мақола20222 иқтибос
ABI
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Ting Yan, Lingfeng Zhu, Jin Chen
Шарҳ мақола20232 иқтибос
ABI
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody +8
Шарҳ мақола20232 иқтибос
ABI
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh +4
Шарҳ мақола20232 иқтибос
ABI
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey +4
Мақола20232 иқтибос
ABI
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17
Мақола20232 иқтибос
ABI
Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors
Xiuxiu Zhu, Jun Chen, Wuling Li +8
Мақола20232 иқтибос
ABI

Ушбу иш иқтибос қилган ишлар

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Up-Regulation of PD-L1, IDO, and T <sub>regs</sub> in the Melanoma Tumor Microenvironment Is Driven by CD8 <sup>+</sup> T Cells

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Tracking the Evolution of Non–Small-Cell Lung Cancer

Tumor Heterogeneity in Breast Cancer

Biomarker concordance between primary colorectal cancer and its metastases

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

CRISPR-engineered T cells in patients with refractory cancer

Memory T cells: strategies for optimizing tumor immunotherapy

CAR-T cell therapy: current limitations and potential strategies

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy

Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors